Top-News

NATTOPHARMA ASA NK 3 News

Keine aktuellen Kursdaten verfügbar
WKN: A0NCUV
ISIN: NO0010289200
Typ: Aktie

NATTOPHARMA ASA NK 3 News

02.06.10 - Hugin
NattoPharma - First Step Into The Pharmaceutical Market
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act) 02.June 2010, Lysaker - Today it was agreed that NattoPharma's ...
23.04.10 - Hugin
Vitamin K experts critical towards simplified message from Emaus' study
23.April 2010, Lysaker - In a recently published study by Emaus et al. at the University of Tromsø (Osteoporos. Int. 2009, Epub ahead of print), the effect of vitamin K2 on bone loss in ...
06.04.10 - Hugin
New study indicate that a daily intake of Vitamin K2 significantly reduce the risk of developing or die of cancer
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act) Recent studies have suggested an anticarcinogenic effect of vitamin ...
09.06.09 - Hugin
HDR Partners, Sweden appointed as strategic advisor.
NattoPharma announced May 4th 2009 that there recently has been established contact with several industrial companies who wish to enter into dialogue about the possible ...
12.02.09 - Hugin
VITAMIN K2 REDUCES WOMEN'S RISK OF CORONARY HEART DISEASE,SPECIFICALLY AS MENAQUINONES 7, 8, & 9
12 February 2009, Lysaker, Norway - NattoPharma and PL Thomas are pleased to notify of a new publication by G. Gast et al. (A high menaquinone reduces the incidence of ...
10.02.09 - Hugin
Danisco and NattoPharma sign global agreement on MenaQ7
Danisco and NattoPharma have entered into long term global supply, marketing and license agreements securing Danisco rights as NattoPharma's sole partner in marketing the ...
03.12.08 - Hugin
Vitamin K is required to inhibit calcium accumulation in thearteries: New Paper in Thrombosis and Haemostasis
December 3rd 2008, Lysaker, Norway - A new publication by Schurgers et al., titled Matrix Gla-​protein: The calcification inhibitor in need of vitamin K elucidates the pivotal importance ...
17.11.08 - Hugin
EFSA opinion strengthens platform for NattoPharma's MenaQ7(TM) inEurope
(Lysaker, Norway 17 November 2008) The European Food Safety Authority (EFSA) has published a positive scientific opinion on vitamin K2, MK-7 from natto as a dietary supplement ...
13.11.08 - Hugin
Low Vitamin K2 Status is A Risk Factor for Hardening of the Arteries- Presented at the American Society of Nephrology Convention
13 November 2008, Lysaker, Norway -NattoPharma and PL Thomas, announced significant exposure and discussion of Vitamin K2 and its role in promoting cardiovascular health ...
14.10.08 - Hugin
BONE QUALITY IN CHILDREN MAY BE COMPRISED BY THERAPY WITH VITAMINK-ANTAGONISTS
14.10.2008, Lysaker, Norway - NattoPharma would like to notify a new publication by Avgeri et al. (J Pediatr Hematol Oncol), about the association of long-term oral anticoagulant ...
14.10.08 - Hugin
NattoPharma acquires MGP Diagnostics and secures rights to importantpatent
NattoPharma ASA has acquired all shares of MGP Diagnostics AS, securing ownership of a granted patent that is the key to the development of a new diagnostic test concept. This ...
11.09.08 - Hugin
NattoPharma secures new distribution agreement
(Lysaker, Norway, 11 September 2008) NattoPharma ASA has entered into an exclusive distribution agreement with Pathway International Pty Ltd for the natural K2 vitamin product ...
10.09.08 - Hugin
ARTERIAL CALCIFICATION REDUCED WITH VITAMIN K2 INTAKE ACCORDING TONEW STUDY IN THE JOURNAL ATHEROSCLEROSIS
10th of September 2008, Lysaker - NattoPharma and PL Thomas are pleased to announce that a new study demonstrated the association of high dietary Vitamin K2 consumption ...
22.08.08 - Hugin
NattoPharma has received the "2008 Frost & Sullivan ProductInnovation of the Year Award"
NattoPharma ASA and PL Thomas proudly announce that NattoPharma's natural vitamin K2 product, MenaQ7(TM), has received the prestigious 2008 Frost & Sullivan Product ...
19.08.08 - Hugin
Presentation of Q2 2008 NattoPharma
On behalf of NattoPharma, Orion Securities would like to invite shareholders, investors and other interested parties to a lunch presentation in connection with the release of ...
16.07.08 - Hugin
Vitamin K deficiency may be a significant risk factor for low bonemass in healthy children and in those with juvenile arthritis
16 July 2008, Lysaker, Norway - NattoPharma and PL Thomas announce today a new study has published in the journal Clinical and Experimental Rheumatology 2008; 26(3):484-...
02.06.08 - Hugin
Interim Report Q1 2008 NattoPharma ASA
Please find enclosed Q1 2008 Interim Report NattoPharma ASA
30.05.08 - Hugin
Q1 2008 Investor Presentation at Orion Securities May 30th 2008
Please find enclosed Q1 2008 Nattopharma Investor presentation to be held at Orion Securities on May 30th 2008
22.05.08 - Hugin
Presentation of Q1 2008 NattoPharma
On behalf of NattoPharma, Orion Securities would like to invite shareholders, investors and other interested parties to a lunch presentation in connection with the release of ...
14.05.08 - Hugin
Annual Report 2007
Please find enclosed the Annual Report 2007 for NattoPharma ASA.

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »